Skip to main
EQ
EQ logo

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Equillium Inc. has demonstrated a robust pipeline of innovative therapies targeting severe autoimmune and inflammatory disorders, notably through its lead candidate itolizumab, which has shown positive top-line data in the EQUALISE study for lupus nephritis, potentially enhancing its competitive positioning in the market. The possibility of Ono exercising its option presents a substantial financial boost of approximately $33 million, which would bolster the company's balance sheet and support further clinical development. Additionally, the anticipation of progressing into pivotal studies by 2025, coupled with the need for safer treatment alternatives compared to existing therapies, lays the foundation for a favorable outlook on Equillium’s stock trajectory.

Bears say

Equillium Inc. is projected to experience significant net losses, with estimates indicating a full-year 2023 net loss of $0.41 per share and a further projected net loss of $0.82 per share in 2025. Additionally, the company's 3Q23 results reflected a net loss of $0.11 per share, and the overall losses for 2023 are anticipated to reach $0.38 per share, compounding concerns about its financial health. The company also faces a reduced probability of approval for its celiac disease treatment, now estimated at only 15%, which negatively impacts its financial outlook and future revenue potential.

Equillium Inc (EQ) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Buy based on their latest research and market trends.

According to 7 analysts, Equillium Inc (EQ) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.97, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.97, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.